We’re kicking off our 2nd half of 2023!!
Join co-chairs @DrHarryThomas and Dr. Tim Ritter in collaboration with GI Alliance on November 18, in Austin!!
🎸New & Returning Speaker Faculty
🎸New Location
🎸Hot #IBD topics
🎸CME
🎸New & returning Vendors
🎸All complimentary to you!
Registration required.
ibdhorizons.org
__
#Texas #Austin #Gastroenterology #IBDHorizons23 #Crohns #InflammatoryBowelDisease #CrohnsDisease #IndeterminateColitis #UlcerativeColitis @IBD_Afzali
1 #IBDHorizons co-founder @IBD_Afzali
+
1 #IBDHorizons23 speaker @MRegueiroMD
————
🆓#IBD symposium talking latest on S1P receptor for #UlcerativeColitis
📅Mon, May 8
🏨Hyatt
🕰️6:00 CT
🧑💻Virtual avail
📄CME/MOC
🎟️http://bit.ly/TChicago23
#DDW2023 #WomenInGI #GITwitter #HereForDDW
---
RT @cQIme
@CWRU_GI @uc_health @IBDHorizons
@ScrubsNHeels @UCincyIM #WomenInGI #GITwitter #HereForDDW
https://twitter.com/cQIme/status/1654644067827961856
If you attended this weekend’s #IBDHorizons23 (in person/virtual), don’t forget to request your CME!!
Follow the directions in program & emails.
1️⃣ http://IBDHorizons.org
2️⃣ Go to resources tab
3️⃣ Activity evaluation
4️⃣ Submit
*Your request must be in by March 25*
#IBDTwitter
What’s on the horizon for #IBDHorizons23
‼️Save the date‼️
📆Dialogues in Seattle!
📆2nd Annual Gulf Coast in Austin!
📆4th Annual APP update in Seattle!
🙏🏽 Thank you for spending the day with us! ~ IBDHorizons team
Recap of #IBDHorizons23
✍️detail IBD history
🌀the right imaging is valuable
🤝IBD care is multi-d
👨🏽🦳Treat early for best outcomes
👩🏻🦱Women have specific IBD needs
🗂️Communicate about 2nd opine
💉current tx safe & work
🔮Exciting pipeline
🙏🏽See you for #IBDHorizons24
Dr #BrianFeagan brings us what’s come about in the studies that took place in 2022/23
💉VDZ treating pouchitis
💊Upa for #UlcerativeColitis
💉Risa approval
💊Combo return of golmumab/guselkumab
💉TL1A monoclonal for fibrostenosing #Crohns
5 IBD therapy misperceptions
❌Therapies are high risk
❌Post-op tx no good
❌Changing tx is based on clinical symptoms
❌IFX is only tx for perianal disease
❌TDM helps achieve remission
*One of the slides is a f/u to a Cincy slide 😉 @MRegueiroMD
How would you answer this Q?
Which of the following is associated with higher rates of malignancy and infections at 1 year compared to placebo:
A - Vedolizumab
B - Ustekinumab
C - Risankizumab
D - None of the above
#IBD patients come for 2nd opinions for a few main reasons & outcomes.
Support patients when they’re desiring a 2nd opinion — you’re working to save a life.
Set up success
Full pmhx
Clear your bias
Explain your opinion
Have clear f/u plan
Communicate w referring
IBDHorizons
Dr Anita Afzali